In China, Promotion Trumps Patents
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - In the late 1980s, Warner-Lambert researcher Bruce Roth came up with atorvastatin and changed the pharmaceutical market, and social and healthcare awareness factors in the West that made Lipitor the biggest blockbuster ever are starting to show up in China and other Asian countries. Cholesterol, heart attacks and the gamut of cardiovascular diseases are on the rise as diets grow richer, lifestyles more sedentary and smoking remains prevalent
You may also be interested in...
China Life Sciences Investment Opportunities Attract Cross Border Tie Ups
HONG KONG - As China ramps up to overtake Japan as the No. 2 pharmaceutical market in coming years, investors are entering the foray to get a foothold in the burgeoning China pharma market and some interesting partners are joining forces
China Life Sciences Investment Opportunities Attract Cross Border Tie Ups
HONG KONG - As China ramps up to overtake Japan as the No. 2 pharmaceutical market in coming years, investors are entering the foray to get a foothold in the burgeoning China pharma market and some interesting partners are joining forces
Korea's Supreme Court Upholds Lower Courts' Ruling against Pfizer's Lipitor Patent Extension
SEOUL - Ending nearly two years of court battles over the patent extension of Pfizer's cholesterol drug Lipitor, South Korea's Supreme Court upheld the lower courts' rulings in favor of six local Korean pharmaceutical companies that have been selling generics of Lipitor (atorvastatin)